Related Experiment Videos
Biliary atresia at the dawn of a new century
1Department of Pediatric Surgery, Chang Gung Children's Hospital. 123, Ta-Pei Road, Niaosung, Kaohsiung, Taiwan, R.O.C. jhchuang@cgmh.or.tw
Insights
Biliary atresia, a serious infant liver condition, requires early diagnosis for better outcomes. While the Kasai operation offers some survival benefits, new gene therapies show promise for future liver rejuvenation.
Area of Science:
- Pediatric Surgery
- Hepatology
- Gastroenterology
Background:
- Biliary atresia is a rare but severe pediatric liver disorder, often necessitating liver transplantation.
- Current survival rates after the Kasai operation at 5 and 10 years without transplantation are 37-48% and 18-28%, respectively.
- The exact cause remains unknown, though viral infections and ductal plate malformation are implicated.
Purpose of the Study:
- To review the current understanding of biliary atresia, including its incidence, prognosis, and treatment outcomes.
- To highlight the importance of early diagnosis and surgical intervention.
- To explore potential future therapeutic strategies, including gene therapy.
Main Methods:
- Literature review of biliary atresia studies.
- Analysis of survival data following the Kasai operation.
- Discussion of pathogenetic mechanisms and emerging treatments.
Main Results:
- Early diagnosis improves prognosis; prolonged jaundice in infants over 2 weeks warrants consideration of biliary atresia.
- The Kasai operation's success is surgeon-dependent, with significant rates of postoperative cholangitis (over 45%).
- Hepatic fibrosis progresses to cirrhosis and failure, even with adequate bile drainage.
Conclusions:
- Biliary atresia requires prompt diagnosis and surgical management (Kasai operation), though outcomes vary.
- Postoperative complications like cholangitis are common and can worsen liver damage.
- Gene therapy targeting liver fibrosis presents a potential future treatment avenue for biliary atresia.
Abstract:
Biliary atresia is a unique disorder in pediatric surgery. The incidence is 1 in 3,500 to 20,000 live births, but the disorder accounts for more than half of the patients requiring liver transplantation. After Kasai operation, the 5- and 10-year survival rate without the need of transplantation are 37-48% and 18-28%, respectively. An infectious pathogen, particularly the virus, has long been implicated as the causative agent of biliary atresia, but none has ever been identified. Ductal plate malformation is likely to be important in the pathogenesis of biliary atresia. Earlier diagnosis is associated with a better prognosis and biliary atresia should be considered in the differential diagnosis of prolonged jaundice in any infants older than 2 weeks of age. The experience of the surgeon and surgical decade are determinant in achieving success of the Kasai operation. Postoperative cholangitis affects more than 45% of the patients receiving Kasai operation and the afflicted patients are at risk of cessation of bile flow and exacerbation of preexisting liver cirrhosis. Hepatic fibrosis starts at the moment when biliary atresia develops and the ongoing inflammation will end up with liver cirrhosis and hepatic failure in most patients, including some with adequate bile drainage. The inhibition of liver cirrhosis in mice or rats by gene therapy, such as telomere gene delivery, transduction with the hepatocyte growth factor gene or blockade of TGF-beta signaling, may provide a new strategy to rejuvenate the ailing liver associated with biliary atresia in the future.